- Report
- April 2025
- 184 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- July 2024
- 182 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- June 2024
- 180 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- May 2024
- 182 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- April 2025
- 124 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- May 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,208GBP
- Report
- August 2024
- 200 Pages
Global
From €4050EUR$4,450USD£3,440GBP
- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2731EUR$3,000USD£2,319GBP
- Drug Pipelines
- April 2025
- 204 Pages
Global
From €2731EUR$3,000USD£2,319GBP
- Report
- July 2024
- 120 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- May 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,208GBP
- Report
- December 2024
- 200 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- August 2024
- 200 Pages
Global
From €3521EUR$3,869USD£2,991GBP
- Report
- July 2024
- 153 Pages
Global
From €3288EUR$3,613USD£2,793GBP
€3868EUR$4,250USD£3,285GBP
- Report
- January 2025
- 48 Pages
Global
From €2275EUR$2,499USD£1,932GBP
- Report
- December 2024
- 51 Pages
Global
From €2275EUR$2,499USD£1,932GBP
- Report
- May 2024
- 90 Pages
United States
From €5416EUR$5,950USD£4,600GBP
- Report
- October 2024
- 134 Pages
North America
From €3641EUR$4,000USD£3,092GBP
- Report
- April 2022
- 400 Pages
Global
€1593EUR$1,750USD£1,353GBP
- Report
- November 2022
- 418 Pages
Global
From €2350EUR$2,766USD£2,066GBP

The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body.
The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more